The global antibody production market is experiencing significant growth, driven by increasing prevalence of cancer and autoimmune disorders. The market size is projected to reach US$ 30.7 billion by 2031, driven by the demand for monoclonal antibodies (mAbs) for targeted treatments and the rising need for tailored therapies.